Baidu
map

Clin Cancer Res:细胞周期蛋白D1依赖性转录程序可预测套细胞淋巴瘤患者的临床预后

2020-10-12 星云 MedSci原创

套膜细胞淋巴瘤(MCL)的特征是t(11;14)(q13;q32)易位导致细胞周期蛋白D1(Cyclin D1)过表达。Cyclin D1是一种主要的细胞周期调控因子,也可以调控转录,但cyclin

套膜细胞淋巴瘤(MCL)的特征是t(11;14)(q13;q32)易位导致细胞周期蛋白D1(Cyclin D1)过表达。Cyclin D1是一种主要的细胞周期调控因子,也可以调控转录,但cyclin D1介导的转录失调对MCL发病机制的影响尚未明确。本研究旨在定义cyclin D1依赖性的基因表达程序并分析其预后价值。

研究人员整合了cyclin D1沉默和过表达细胞的全基因组表达分析和cyclin D1染色质结合谱,以鉴别MCL细胞中cyclin D1依赖性的转录程序。并在两个MCL系列外周血样本(n=53)和淋巴组织(n=106)中分析了该基因程序,以确定其生物学和临床相关性。最后还在一个独立的MCL系列外周血样本(n=81)验证了其研究结果。

研究人员发现cyclin D1依赖性的转录程序包含295个基因,主要涉及细胞周期调控。cyclin D1依赖性的基因程序在MCL肿瘤中过表达,与cyclin D1水平呈正比。该程序高表达可提示患者预后不良,显著缩短患者的总体生存期。这些结果在第三MCL队列中通过一个简化的37基因cyclin D1签名均得到了验证。此外,cyclin D1依赖性的转录程序在cyclin D1过表达的多发性骨髓瘤和乳腺肿瘤中也存在。

总而言之,本研究发现了一个细胞周期蛋白D1(cyclin D1)依赖性的转录程序,在MCL中过表达,并可预测患者的临床预后。

原始出处:

Santiago Demajo, et al. A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma. Clin Cancer Res. October 12 2020 DOI:10.1158/1078-0432.CCR-20-2868

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Jan 28 20:25:21 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904795, encodeId=1419904e9503, content=6666666, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c675249972, createdName=147dc146m87(暂无昵称), createdTime=Fri Dec 04 10:50:37 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747410, encodeId=3a781e474103c, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Oct 17 15:25:21 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287529, encodeId=d7aa128e529e4, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534750, encodeId=db1f1534e5080, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Jan 28 20:25:21 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904795, encodeId=1419904e9503, content=6666666, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c675249972, createdName=147dc146m87(暂无昵称), createdTime=Fri Dec 04 10:50:37 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747410, encodeId=3a781e474103c, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Oct 17 15:25:21 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287529, encodeId=d7aa128e529e4, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534750, encodeId=db1f1534e5080, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-12-04 147dc146m87(暂无昵称)

    6666666

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Jan 28 20:25:21 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904795, encodeId=1419904e9503, content=6666666, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c675249972, createdName=147dc146m87(暂无昵称), createdTime=Fri Dec 04 10:50:37 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747410, encodeId=3a781e474103c, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Oct 17 15:25:21 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287529, encodeId=d7aa128e529e4, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534750, encodeId=db1f1534e5080, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
    2020-10-17 mjldent
  4. [GetPortalCommentsPageByObjectIdResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Jan 28 20:25:21 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904795, encodeId=1419904e9503, content=6666666, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c675249972, createdName=147dc146m87(暂无昵称), createdTime=Fri Dec 04 10:50:37 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747410, encodeId=3a781e474103c, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Oct 17 15:25:21 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287529, encodeId=d7aa128e529e4, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534750, encodeId=db1f1534e5080, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1702654, encodeId=a3511e0265488, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Jan 28 20:25:21 CST 2021, time=2021-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904795, encodeId=1419904e9503, content=6666666, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c675249972, createdName=147dc146m87(暂无昵称), createdTime=Fri Dec 04 10:50:37 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747410, encodeId=3a781e474103c, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Oct 17 15:25:21 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287529, encodeId=d7aa128e529e4, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534750, encodeId=db1f1534e5080, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Wed Oct 14 13:25:21 CST 2020, time=2020-10-14, status=1, ipAttribution=)]

相关资讯

Clini Cancer Research:新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL

BTK大量表达,使BCR通路的异常激活,会影响B细胞的增殖、分化和凋亡,从而引发各种恶性淋巴瘤。本研究旨在评估一种新型BTK抑制剂zanubrutinib用于MCL的疗效和安全性。

Baidu
map
Baidu
map
Baidu
map